Figure 1From: Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer Overall survival (OS) and progression-free survival (PFS) for 130 patients treated with stereotactic ablative radiotherapy (SABR) for stage I NSCLC. Back to article page